Lifirafenib
Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
Product Specifications
CAS Number
[1446090-79-4]
Product Name Alternative
BGB-283
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR; Raf
Type
Reference compound
Related Pathways
JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BGB-283.html
Purity
98.01
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14 (10) :2187-97.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
B-Raf; EGFR/ErbB1/HER1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15321973 1 Vial
Lentiviral human ERMN shRNA (UAS) - Lentiviral human ERMN shRNA (UAS, GFP) plasmid
Ask
View Details 